bovnews27m
Takeda Pharmaceutical Co Ltd (TAK) Stock: Beyond the Surface of Its Performance?
Takeda Pharmaceutical Co Ltd (TAK) stock saw a modest uptick, ending the day at $13.32 which represents a slight increase of $0.07 or 0.53% from the prior close of $13.25. The stock opened at $13.23 ...
The Impact and Trends of Review Designations in the Pharmaceutical Industry
The "Pharmaceutical Review Designations: Trends and Industry Insights" report has been added to ResearchAndMarkets.com's offering.This report investigates review designations in the pharmaceutical ...
Adrenocortical Carcinoma Market Poised For Major Growth By 2034 Delveinsight
Industry giants like Takeda Pharmaceuticals, Pfizer, Novartis, and Bayer are revolutionizing treatment landscapes, paving the way for enhanced patien ...
Novo Nordisk (NVO) Receives a Buy from TD Cowen
In a report released today, Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report). The company’s ...
Neurocrine Biosciences chief medical officer sells $222,636 in stock
Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold shares of the company's common stock. According to a recent SEC filing, Roberts sold 1,457 shares on January 31 at an average price ...
Neurocrine Biosciences CFO sells shares worth $196,135
Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $15.4 billion biopharmaceutical company that has delivered an impressive 11.7% return year-to-date, reported a stock sale by Chief Financial Officer Matt ...